We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Protein Panel Developed for Early Detection of Lung Cancer

By LabMedica International staff writers
Posted on 18 Sep 2019
Lung cancer is the most common cause of cancer-related mortality worldwide, characterized by late clinical presentation as 49%–53% of patients are diagnosed at stage IV, and consequently have poor outcomes.

Screening with low-dose computed tomography (LDCT) has proven effective at reducing lung cancer mortality in high-risk populations, but there is still considerable uncertainty and debate about how to best define these populations. More...
Currently, this is primarily done based on age and smoking history, but protein and other biomarkers could play a role as well.

Scientists at the University of Manchester (Manchester, UK) analyzed 50 serum samples from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) biobank, 25 from healthy controls and 25 from patients who were diagnosed with lung cancer within 50 months of the blood draw. The team used blood collected during surgical resection of lung tumors in an iTRAQ isobaric tagging experiment to identify proteins effluxing from tumors into pulmonary veins.

The team used sequential window acquisition of all theoretical fragment ion spectra (SWATH) on a Sciex TripleTOF 6600 mass spectrometer to analyze the serum samples. The samples were run using a two-hour liquid chromatograph (LC) gradient, and they identified 65 proteins that were differentially expressed between the two groups. Using hierarchical clustering and principal component analysis, they identified a panel of 11 proteins that distinguished between cases and controls one year prior to diagnosis with sensitivity of 88% and specificity of 89%. A 12-protein panel that included a marker identified by earlier research was able to distinguish between cases and controls at three years to diagnosis with sensitivity of 79% and specificity of 78%.

Anthony D. Whetton, PhD, a Professor and lead author of the study, said, “I think the ideal is that we have a blood-borne biomarker test for risk and stratification, so that one can look at the results of this test and determine whether further follow-up is required. I think that's the space that is awfully important with respect to lung cancer.” The study was published on August 13, 2019, in the Journal of Proteome Research.

Related Links:
University of Manchester


Gold Member
Veterinary Hematology Analyzer
Exigo H400
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Host Response Immunoassay Test
MeMed BV
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.